How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

April 30, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

exenatide

5mcg twice a day, increasing to 10mcg twice a day for 24 weeks

DRUG

placebo

5mcg twice a day, increased to 10mcg twice a day for 24 weeks

Trial Locations (3)

20003

Medstar Research Institute, Washington D.C.

55905

Mayo Clinic, Rochester

97239

Oregon Health and Science University, Portland

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT00667732 - How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics | Biotech Hunter | Biotech Hunter